MicroRNAs drive liver cancer regulation and offer new treatment hope

Hepatocellular carcinoma, the most common form of primary liver cancer, remains one of the deadliest malignancies in the world, and a newly published comprehensive review is shining a spotlight on a class of tiny genetic molecules that may hold the key to both earlier diagnosis and more effective treatment. The review, published in the open-access journal Cancer Cell International, systematically examines the roles of microRNAs in hepatocellular carcinoma, detailing how these short RNA fragments orchestrate nearly every aspect of tumor behavior, from uncontrolled cell division and metastasis to immune evasion and metabolic rewiring. Written by Bolang Liu, Xinjun Lu, Jin Li and Yi Zhang, with corresponding author Yi Zhang based at the School of Pharmacy and Bioengineering at Chongqing University of Technology, the work arrives at a moment when clinicians desperately need new weapons against a disease whose prognosis has stubbornly resisted improvement for decades.

MicroRNAs are small, non-coding RNA molecules, typically only 19 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression after transcription. Their mechanism of action is elegant in its simplicity: a microRNA associates with a protein complex known as the RNA-induced silencing complex, or RISC, and uses its sequence to recognize complementary stretches of messenger RNA, most commonly within the 3′-untranslated region of target transcripts. When binding occurs, the microRNA either promotes degradation of the messenger RNA or blocks its translation into protein, effectively turning down the volume on specific genes. Because a single microRNA can target hundreds of different messenger RNAs, and because each messenger RNA can be regulated by multiple microRNAs, these molecules form dense regulatory networks that influence virtually every cellular pathway. In the liver, where microRNAs help maintain the delicate balance between regeneration and quiescence, disruption of these networks can tip cells toward malignant transformation.

What makes microRNAs particularly fascinating in the context of cancer is their dual nature. Depending on the genes they target, individual microRNAs can act either as oncogenes, promoting tumor growth when they suppress protective factors, or as tumor suppressors, restraining cancer when they silence growth-promoting genes. The new review catalogs dozens of examples of this duality in hepatocellular carcinoma. Tumor-suppressive microRNAs frequently rein in the activity of critical signaling cascades, whereas oncogenic microRNAs, often overproduced in tumor cells, dismantle the cell’s natural brakes on proliferation. This yin-and-yang quality means that therapeutic strategies must be carefully tailored: restoring a lost tumor-suppressive microRNA requires replenishing it, while silencing an overactive oncogenic microRNA demands inhibitors, often chemically modified antisense oligonucleotides designed to bind and neutralize the offending molecule.

At the heart of the review’s technical analysis lies the interplay between microRNAs and four major signaling pathways that dominate hepatocellular carcinoma biology. The first, the Wnt/β-catenin pathway, is a master regulator of liver development and regeneration. In healthy cells, the protein β-catenin is continuously targeted for destruction by a destruction complex containing the adenomatous polyposis coli protein, or APC, and axis inhibition protein, Axin, along with glycogen synthase kinase 3 beta. When this complex is disabled, β-catenin accumulates, enters the nucleus, and partners with T-Cell Factor 4 to activate genes driving cell division. The review describes how microRNAs can influence this pathway at multiple points, either promoting β-catenin degradation or, conversely, silencing its negative regulators such as PTEN, the phosphatase and tensin homolog that restrains parallel growth signaling. The result is a pathway that tumor cells exploit with remarkable consistency, and one that microRNA-based therapies could theoretically recalibrate.

The second major axis involves the PI3K/AKT/mTOR pathway, a growth-control circuit that transduces signals from receptor tyrosine kinases at the cell surface into metabolic and survival programs within the cell. When phosphatidylinositol phosphate signaling activates AKT, the kinase phosphorylates a host of downstream targets, including members of the Forkhead box O transcription factor family, promoting cell survival and blocking programmed cell death. Multiple microRNAs in hepatocellular carcinoma converge on this pathway, frequently by suppressing PTEN, the lipid phosphatase whose loss unleashes unrestrained AKT signaling. The review also highlights the TGF-β/Smad pathway, a signaling system with paradoxical roles that suppress tumor growth early in carcinogenesis but later fuel invasion and metastasis through epithelial-mesenchymal transition, a process in which epithelial cancer cells shed their adhesive properties and acquire the motile, invasive characteristics of mesenchymal cells. Transcription factors such as Zinc finger E-box binding homeobox 1, or ZEB1, orchestrate this transition, and microRNAs that regulate ZEB1 and related factors can either accelerate or restrain metastatic spread. Finally, the MAPK/ERK cascade, which relays signals from the Kirsten rat sarcoma viral oncogene homolog, KRAS, through rapidly accelerated fibrosarcoma, RAF, and mitogen-activated protein kinase kinase, MEK, to extracellular signal-regulated kinase, ERK, is another frequent microRNA target, with regulators such as the Sprouty RTK signaling antagonist 2 modulating the intensity of proliferative signals.

Beyond these canonical pathways, the review devotes considerable attention to how microRNAs reshape the tumor microenvironment, the complex ecosystem of immune cells, fibroblasts, blood vessels and extracellular matrix that surrounds and supports the tumor. Hepatocellular carcinoma is a notoriously inflammatory cancer, arising most often in livers scarred by chronic hepatitis B virus infection, hepatitis C virus infection, alcohol-related damage or metabolic dysfunction-associated steatotic liver disease. Within the tumor microenvironment, tumor-associated macrophages, cancer-associated fibroblasts and hepatic stellate cells communicate with malignant cells through cytokines and chemokines, including C-C motif chemokine ligand 2 and macrophage migration inhibitory factor. MicroRNAs mediate much of this crosstalk. Some microRNAs secreted by tumor cells within extracellular vesicles travel to recipient immune cells and reprogram them toward a pro-tumor state, dampening the activity of natural killer cells and cytotoxic T lymphocytes. Others influence the expression of programmed death-ligand 1, PD-L1, the molecular shield that tumors use to evade immune checkpoint blockade, suggesting that microRNA levels could predict which patients will respond to immunotherapy. Hypoxia-inducible factor 1 alpha, the master transcriptional response to low oxygen, also intersects with microRNA networks to promote angiogenesis and metabolic adaptation in oxygen-starved tumor regions.

Metabolic reprogramming, a hallmark of cancer in which tumor cells alter how they generate energy and build biomass, emerges as another major theme. The review details how microRNAs regulate glycolysis through targets such as hexokinase 2, modulate glutamine and serine metabolism, and restructure lipid biochemistry by controlling enzymes including stearoyl-CoA desaturase-1, glycerol-3-phosphate acyltransferase, and carnitine palmitoyl transferase 1C, which governs fatty acid oxidation. MicroRNAs also influence the mevalonate pathway, fatty acid-binding proteins, and the consumption of coenzyme Q10 within mitochondrial fatty acid oxidation complexes such as hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha. Even lactate transport, through monocarboxylate transporter 1, falls under microRNA control. These metabolic regulators matter clinically because metabolic dysfunction-associated steatotic liver disease and its inflammatory progression to metabolic dysfunction-associated steatohepatitis are rapidly becoming leading drivers of liver cancer worldwide, meaning that microRNA networks sit at the intersection of tumor metabolism and the metabolic disease environment of the host liver.

The review also addresses how microRNAs shape more specialized malignant behaviors, including the maintenance of cancer stem cells, the subpopulation of tumor cells capable of self-renewal and of seeding recurrence after treatment. Epigenetic regulators such as SET domain bifurcated histone lysine methyltransferase 1 and the chromobox homolog 4 protein, as well as DNA repair and stress-response factors including BRCA1-associated protein 1, superoxide dismutase 1, and the solute carrier family 7 member 11 involved in antioxidant defense, are all subject to microRNA regulation. Long noncoding RNAs and circular RNAs add another layer of complexity, acting as molecular sponges that sequester microRNAs and thereby soften their repressive effects, a phenomenon known as competing endogenous RNA regulation. This dense interplay among RNA species means that microRNA activity in a tumor reflects not just its own abundance but the entire non-coding RNA landscape, offering a rich source of potential biomarkers.

On the clinical translation front, the authors evaluate microRNAs both as diagnostic tools and as therapeutic targets. Circulating microRNAs in blood plasma and serum are remarkably stable, protected from degradation by association with proteins or enclosure in extracellular vesicles, making them attractive minimally invasive biomarkers, so-called liquid biopsies, for detecting hepatocellular carcinoma earlier and monitoring treatment response. On the therapeutic side, the field has already produced one landmark success: the tumor-suppressive microRNA mimic known as TargomiRs and, more pertinently for liver disease, the microRNA-122 antisense inhibitor miravirsen, which reached clinical testing as an antiviral agent against hepatitis C virus. For hepatocellular carcinoma itself, strategies under investigation include viral vectors carrying tumor-suppressive microRNAs, lipid nanoparticles delivering microRNA mimics, and antisense oligonucleotides silencing oncogenic microRNAs. Challenges remain formidable, however, including targeted delivery to tumor cells while sparing healthy hepatocytes, the risk that a single microRNA affects unintended genes in normal tissue, dose-limiting toxicity, and the heterogeneity of microRNA expression among patients.

The authors emphasize that these obstacles, while significant, are not insurmountable. Advances in extracellular vesicle engineering, chemically stabilized nucleic acid therapeutics, and combination regimens pairing microRNA therapies with existing multitarget tyrosine kinase inhibitors or immune checkpoint inhibitors are steadily expanding the therapeutic toolkit. The regulatory networks mapped in this review provide a roadmap for identifying which microRNA interventions are most likely to synergize with current treatments, and which patient subgroups, defined by viral etiology, metabolic status or molecular subtype, stand to benefit most. As hepatocellular carcinoma continues to claim hundreds of thousands of lives each year, the humble microRNA, a molecule barely two decades old in the scientific consciousness, is proving to be far more than a curiosity; it is emerging as a central orchestrator of cancer biology and a genuinely promising frontier in the fight against one of humanity’s most lethal cancers. The research was supported by the National Natural Science Foundation of China and the Science and Technology Research Program of Chongqing Municipal Education Commission.